5 News & Press Releases found
CIS Pharma AG News
-
Preclinical development of a novel radiopharmaceutical bioconjugate with the potential to cross the blood brain barrier
CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to develop a nanobody-radionuclide conjugate, currently at preclinical stage. The bioconjugate is based on ...
-
Feasibility study initiated to develop a novel drug carrier to deliver oligonucleotides, ASO and siRNA
CIS Pharma has initiated a feasibility study to develop a novel carrier to conjugate ASO and siRNA for targeted delivery, in collaboration with the University of Applied Sciences in Basel. To widen the therapeutic use of oligonucleotides, CIS ...
-
Patent application published covering novel technology to improve contact lens care solutions
CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS ...
-
CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier
CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a SKOvip mouse model, an aggressive form of ovarian cancer. The ARC ...
-
CIS Pharma contact lens care solution shows enhanced biocompatibility, unsurpassed concentration of hyaluronic acid and a powerful disinfection complex
CIS Pharma has successful up-scaled the production of its novel contact lens multipurpose and disinfection solution (MPDS) to an industrial setup. The contact lens care solution achieved excellent performance compared to products that are leading ...